They accuse their neurologists and the French drug manufacturer Sanofi, which produces Depakine, of failing to warn them about the risks to the fetus, according to reports published on Le Matin Dimanche and SonntagsZeitung.
Depakine is still widely used today to treat epilepsy and migraines. Scientists have established that the sodium valproate contained in the drug creates psychomotor, cognitive and mental development disorders in 30 to 40% of cases.
The Swiss expecting mothers were not made aware of these dangers. A warning from agency for therapeutic products, Swissmedic, came to late.
In Switzerland, 39 children have been born with brain damage in connection to Depakine use, according to a report commissioned by the government.
Thierry Buclin, a professor of clinical pharmacology at the University Hospital of Lausanne suspects the actual figure is much higher.
The professors, who was quoted in the media reports, says the government study is incomplete. It does not consider the transgenerational effect of Depakin which has been brought to light by recent scientific studies.
The controversial drug has been authorised in Switzerland since the 1970s. Such side effects were not mentioned in the package leaflet until 2015.
In neighbouring France, as many as 6,500 children have been negatively affected by Depakine. The victims launched a collective action against Sanofi at the end of 2016 to obtain compensation.
The first complaint was made in Switzerland in 2017 by a woman who had been using the drug since adolescence and even had her dosage raised by her neurologist during one of her pregnancies. She gave birth to two children who suffer from severe cognitive disorders and autism.
Popular Stories
More
Workplace Switzerland
What lies ahead for Switzerland: an economic outlook for 2025
Have you heard something about Swiss diplomacy that you’d like us to fact check?
Not all information circulating about Switzerland’s foreign relations is accurate or well understood. Tell us what you'd like us to fact check or clarify.
SWISS crew member ‘died as a result of oxygen deprivation’
This content was published on
SWISS crew member reportedly died of brain damage resulting from lack of oxygen, following an emergency landing last month.
Zurich flights cancelled due to snow and freezing rain
This content was published on
Snowfall and freezing rain severely disrupt air traffic at Zurich airport over the weekend, with more than 50 flights being cancelled.
Terror threat rising in Switzerland, says Attorney General
This content was published on
The number of active terrorism investigations in Switzerland has doubled since 2022, according to the country’s top prosecutor.
Credit Suisse Nazi ties ‘ran deeper than thought’: media report
This content was published on
Credit Suisse is alleged to have withheld details of its historic links with World War II-era Nazi clients, says the Wall Street Journal.
Swiss man faces life imprisonment after Australia drugs arrest
This content was published on
Swiss man, 21, accused of attempting to smuggle 25 kilograms of cocaine with a street value of CHF4.5 million into Australia.
Swiss insurer Helvetia says 500 jobs affected by cost-cutting
This content was published on
Some 500 jobs, including 200 to 250 in Switzerland, are affected by the new operational efficiency measures recently announced by insurer Helvetia.
This content was published on
Significantly fewer new cars were sold in Switzerland in 2024 than the previous year as demand for electric cars and plug-in hybrids declined.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis and Microsoft to develop drugs using AI
This content was published on
Novartis and Microsoft have signed a five-year partnership aimed at transforming the Basel-based pharma’s business using AI.
Gaps found in opioid prescription oversight in Switzerland
This content was published on
In the wake of the opioid crisis in the US, some medical professionals in Switzerland are warning about over-prescription of oxycodone drugs.
Swiss pharmaceutical firm lets dogs die cruel death
This content was published on
Dogs are being left to die in agony in Germany after lab testing for the Swiss pharma company Inthera Bioscience, says a report.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.